Cancer Therapeutic based on Stimulation of Natural Killer T-cell Anti-tumor Activity


Natural killer T cells (NKT) are a unique lymphocyte population that has T-cell and NK cell functional properties in order to rapidly elicit an immune response.  alpha-galactosylceramide (alpha-GalCer) is a potent NKT stimulator and induces of IFN-gamma release to promote immunity against tumors and infectious agents.  Humans have natural antibodies against alpha-galactose, which may be one of the reasons why the human clinical trials of alpha-GalCer or KRN7000 were not very successful.

Beta-ManCer is a new class of NKT agonist that induces immune responses alone, through nitric oxide and TNF-alpha-dependent mechanisms, or synergistically with alpha-GalCer to enhance alpha-GalCer''s efficacy.  Since beta-ManCer does not have alpha-galactose, which can be neutralized by natural antibodies, patients could be treated with multiple doses without negative side effects associated with the loss of IFN-gamma production.  Hence, beta-ManCer is a promising anti-cancer treatment either alone or in combinatorial therapies with alpha-GalCer to selectively induce immune responses.



Potential Commercial Applications: Competitive Advantages:
  • Cancer therapeutics
  • Potent stimulator of NKT activity
 
  • Induces tumor immunity through a novel mechanism
  • Decreased possibility of neutralization by natural antibodies
  • Synergize with alpha-GalCer


Development Stage:
Discovery (Lead Identification)

Inventors:

Masaki Terabe (NCI)  ➽ more inventions...

Ira Pastan ()  ➽ more inventions...


Intellectual Property:
U.S. Provisional Application No. 61/313,508

Collaboration Opportunity:

Licensing only


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-034-2010
Updated: Jul 19, 2018